ISSN: 2161-0711

Médecine communautaire et éducation à la santé

Accès libre

Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.

Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs

Abstrait

A Systematic Review on Evolving the Bowel Cancer Screening Programme in England: Targeted Screening for Individuals with First Degree Family History of Bowel Cancer

Rutendo L Chigonda

First degree relatives of bowel cancer cases have an approximately twofold risk of the disease compared with those without a family history, and the more affected first degree relatives an individual has, the higher the absolute and relative risk for developing bowel cancer. At present, widespread screening of average risk individuals for bowel cancer occurs in England; however, the Bowel Cancer Screening Programme does not currently provide a framework for the identification of a family history of bowel cancer. The aim is to determine the cost effectiveness and benefits of offering targeted screening to individuals with a first degree family history of bowel cancer. The primary outcomes examined the prevalence of developing bowel cancer and estimated the cost effectiveness to inform screening policy decisions. The secondary outcome evaluated the possible screening barriers in the adoption of bowel screening of first degree relatives. Data presented suggests that screening first degree relatives of patients with bowel cancer is likely to be cost effective to the NHS, and that compared with the average risk group using colonoscopy, advanced neoplasia was significantly more prevalent in those with first degree relatives with bowel cancer. Targeted screening would mean less long term health costs however, given the limited resources on NHS cost analysis data, cost savings associated with targeted screening are largely unknown; although data presented from European studies strongly suggests that it may be optimistic. Opportunities for this review include its recommendation to modify the screening criteria to extended to first degree relatives of bowel cancer patients and for the National Screening Committee to implement this protocol nationwide.